+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effect of pegloticase given by two different methods along with methotrexate in adults with uncontrolled gout. This phase 3 trial compares subcutaneous under the skin injections of pegloticase at 18 mg every two weeks with intravenous into a vein injections of pegloticase at 8 mg every two weeks, both combined with weekly methotrexate. The main goal is to see which approach better maintains low serum uric acid levels during the sixth month. Participants will be randomly assigned to receive either pegloticase by subcutaneous injection or by intravenous infusion, both administered every two weeks, alongside oral methotrexate taken weekly. The trial is double-blind, meaning neither participants nor researchers know which form of pegloticase is given. Methotrexate is given orally concurrently. Treatment continues through at least six months with ongoing evaluations. During the study, participants will have regular assessments to monitor their response to treatment, including blood tests to measure serum uric acid levels and pegloticase concentrations. Safety will be closely observed, including monitoring for injection site reactions, infusion reactions, and anaphylaxis up to 48 weeks. The primary outcome measures participants who maintain normalized uric acid levels during Month 6, with follow-up lasting up to 48 weeks. Total participation may extend to the study completion in June 2028.

Age: 18Years +All GendersPhase 3
75 locations
R

Actively Recruiting

Researchers are evaluating the effects of YB-101 on thyroid function in people with Graves Disease. This trial aims to assess how safe and well tolerated YB-101 is, as well as how it is distributed in the body. The study includes two parts a first blinded treatment period and a second double-blinded treatment period, where participants receive either YB-101 or a placebo. Participants receive YB-101 or placebo through subcutaneous injections over a 24-week period. Those in Part 1 will not be eligible to join Part 2. The study involves approximately 34 to 39 visits at the clinic over about 40 weeks, depending on whether participants are in Part 1 or Part 2. Throughout the study, participants will attend many clinic visits to monitor their health and response to the treatment. Researchers will track adverse events and measure thyroid hormone levels including free triiodothyronine, free thyroxine, and thyroid-stimulating hormone. The study will also observe whether participants can stop anti-thyroid drugs regardless of levothyroxine use. Safety, tolerability, and effects on thyroid function will be assessed until about Day 169 of treatment.

Age: 18Years +All GendersPhase 2
32 locations
R

Actively Recruiting

Researchers are evaluating the effect of olpasiran compared to a placebo on the risk of coronary heart disease death, heart attack, or urgent coronary revascularization in people at risk for a first major cardiovascular event who have elevated lipoproteina levels. This phase 3 study focuses on participants aged 50 to 105 years with multiple cardiovascular risk factors or evidence of atherosclerosis. Participants will be randomly assigned to receive either subcutaneous injections of olpasiran or a placebo. The study is designed as a double-blind, placebo-controlled trial, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period spans up to approximately 6.2 years, during which participants receive regular injections and monitoring. Throughout the study, participants will be assessed for the time until coronary heart disease death, myocardial infarction, or urgent coronary revascularization occurs. Additional measurements include changes in lipoproteina levels and monitoring of cardiovascular events, strokes, and safety through adverse event tracking. Participants will have regular evaluations over the treatment duration, ensuring close follow-up until study completion.

Age: 50Years - 105YearsAll GendersPhase 3
252 locations
L

Actively Recruiting

This research aims to evaluate the long-term efficacy and safety of ianalumab treatment in adults with lupus nephritis who have completed the SIRIUS-LN core study. The study focuses on two groups patients who achieved complete or partial renal response and stopped study treatment, and those who continue or start open-label ianalumab because they did not meet response criteria or were already receiving it. This open-label extension can last up to six years. Participants are divided into two cohorts. Cohort 1 includes patients who responded to previous treatment and will withdraw from the study drug while continuing standard care, with the option to restart ianalumab if they experience renal flare. Cohort 2 includes patients who did not respond or were already on open-label ianalumab and will continue receiving this treatment during the extension. The study allows investigators to decide if continuing in the extension is beneficial for each participant. Throughout the study, participants will be monitored for kidney flare-ups, changes in immunosuppressive medication, adverse events, and the presence of antibodies against ianalumab. Assessments include safety and efficacy measures over up to six years, with the primary outcomes focusing on time to renal flare or adverse events depending on the cohort. Participants will have regular evaluations to track their health status and treatment effects during this period.

Age: 18Years - 100YearsAll GendersPhase 3
51 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness and safety of LUPKYNIS combined with belimumab, obinutuzumab, or anifrolumab in adults with lupus nephritis LN. The study focuses on how well these combinations induce a rapid kidney response in patients diagnosed with LN, a condition affecting kidney health. It is a phase 4 clinical trial sponsored by Aurinia Pharmaceuticals Inc. that assesses treatment approaches for this condition. Participants will receive LUPKYNIS along with one of the biologic agents belimumab, obinutuzumab, or anifrolumab. In addition, all patients will be treated with a mycophenolic acid analog MPAA, such as mycophenolate mofetil or mycophenolic acid, and corticosteroids like prednisone or an equivalent. The biologic treatment schedules vary depending on the specific drug, with some patients already receiving treatment before the study starts or beginning it at the start of the trial. During the study, participants will be monitored for kidney response over 24 weeks, including complete and partial renal responses. Researchers will assess safety by tracking treatment-emergent adverse events up to 28 weeks. Other assessments include measuring changes in kidney-related antibodies and complement levels at baseline, 12 weeks, and 24 weeks. The total participation duration extends to about 28 weeks, during which various evaluations, laboratory tests, and safety monitoring will occur to understand treatment effects and patient outcomes.

Age: 18Years - 75YearsAll GendersPhase 4
27 locations
E

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the Shield blood tests performance for colorectal cancer CRC screening in people aged 45 to 81 who are at average risk for CRC. The study focuses on assessing the test during a second round of screening, using colonoscopy as the reference standard. CRC is a common and serious disease, especially affecting older adults and certain minority groups, with early detection being key to improving outcomes. Participants will undergo the Shield blood test as part of their routine standard care, and their results will be compared to colonoscopy findings. This study is observational and collects real-world evidence over a period of 33 to 42 months after enrollment to assess how well the Shield test performs in detecting CRC or its precursors during the second screening interval. Participants will be involved in scheduled study procedures and standard care assessments, with data collected on the tests accuracy and effectiveness over time. The main outcome measured is the performance of the Shield test during the second testing period. The study will continue until December 2030, monitoring participants to gather long-term information about CRC screening efficacy in an average-risk population.

Age: 45Years - 81YearsAll Genders
69 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of BHV-1300 in adults with Graves disease who have active hyperthyroidism. This Phase 3, randomized, placebo-controlled study aims to better understand how BHV-1300 may help regulate thyroid function in this population. Participants will be randomly assigned in a 21 ratio to receive either BHV-1300 or a matching placebo. Both treatments are administered by subcutaneous injection using an autoinjector. The study compares these two groups to assess their impact on thyroid hormone levels and antibody status over a 26-week period. During the study, participants will be monitored for thyroid function, antibody levels, and safety outcomes such as adverse events and lab abnormalities. Researchers will measure thyroid hormone levels and antibody changes at various timepoints, with the main focus at Week 26. Participants will also be tracked for their use of antithyroid drugs and overall tolerability of the treatments throughout the study.

Age: 18Years - 70YearsAll GendersPhase 3
56 locations